207 results
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
EXHIBIT 99.1
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT … in patients with relapsed/refractory NHL, CLL and RT, combined with our unique, innovative decentralized manufacturing approach that enables a seven-day vein
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
molecules, CAR-T therapies and biologics in oncology and immunology. We continue to take steps to transform into an innovative pure-play biotech … experience. This innovative platform consists of an end-to-end xCellit® workflow management and monitoring software system, a decentralized, functionally
6-K
EX-99.7
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
billion upfront payment from Gilead Sciences, and (ii) Gilead Sciences gained exclusive access and certain rights to the Company’s innovative portfolio … on developing innovative medicines for life-threatening diseases. Simultaneously with the execution of the Subscription Agreement, the Company
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
last month, we are moving forward with a streamlined portfolio and enhanced focus on our differentiated and innovative pipeline. We are determined
6-K
EX-99.1
ln4m4yq686ga
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
bgv sr8p8347d2mjt9pa
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
8lvsbd5
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
ndux9t
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
x9xm2bei25x
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
6byo8
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
8sdt68icc 1a01
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
xip3vrac0x
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.2
ctdb8k5z
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
k1uel4 4624t
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
csj6741qfk0dh2xh4ovd
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
euwk30
9 May 23
Galapagos creates new subscription right plans
5:02pm
6-K
EX-99.1
jingil0e4jnf
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
quc50qn4gnngo 6j5ub
2 May 23
Current report (foreign)
4:15pm
6-K
EX-99.1
qc3n8pc0lpbbp
26 Apr 23
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
8:23am